Jun 21, 2020
Ascentage Pharma Enters Clinical Collaboration to Evaluate the Combination of Bcl-2 and BTK Inhibitors
Oct 09, 2019
Nordic Nanovector Presentations at the Annual Congress of the European Association of Nuclear Medicine (EANM)
Jul 26, 2019
Information Update - Multiple unauthorized sexual enhancement products seized from Convenience Plus Video in East York, Ontario, may pose serious health risks
Jul 05, 2019
Information Update - Multiple sexual enhancement products seized from five stores in Scarborough, Ontario, may pose serious health risks
Jun 05, 2019
Men's Health Month: Media Highlights GAINSWave®, As Most Innovative Solution for Men Looking to Optimize Erectile Quality and Fix Erectile Dysfunction
Feb 14, 2019
Ascentage Pharma Appoints Jeff Kmetz as Chief Business Officer
Jan 28, 2019
U.S. FDA Approves IMBRUVICA® (ibrutinib) Plus Obinutuzumab as First Non-Chemotherapy Combination Regimen for Treatment-Naïve Patients with Chronic Lymphocytic Leukemia
Dec 13, 2018
Erectile Dysfunction Drugs Market to Touch US$ 2.87 Billion by 2026; Introduction of Generic Substitutes to Support the Market, Says TMR
Dec 03, 2018
IMBRUVICA® (ibrutinib) Plus Obinutuzumab Showed Significant Improvement in Progression-Free Survival Compared to Chlorambucil Plus Obinutuzumab in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Dec 02, 2018
IMBRUVICA® (ibrutinib) Data in Chronic Lymphocytic Leukemia (CLL) Show up to Seven Years of Progression-free Survival (PFS) in 80 Percent of Previously Untreated Patients, the Longest Follow-up for a Bruton's Tyrosine Kinase Inhibitor to Date
Nov 14, 2018
Advisory - "Vita-X Revitalizing Capsules" for men may pose serious health risks
Nov 07, 2018
Information Update - Unauthorized Vita-X and J-Up sexual enhancement capsules seized from Kitchen Food Fair in Etobicoke and Hung Phat Grocery in Ottawa because they may pose health risks
Sep 05, 2018
Information Update - Unauthorized sexual enhancement products seized from Kitchen Food Fair stores in Ontario may pose serious health risks
Aug 27, 2018
U.S. FDA Approves IMBRUVICA® (ibrutinib) Plus Rituximab as First Non-Chemotherapy Combination Regimen for Patients with Waldenström's Macroglobulinemia, a Rare Blood Cancer
Aug 13, 2018
Chronic Lymphocytic Leukemia (CLL) Market Insights, Epidemiology and Market Forecast to 2027
Jul 11, 2018
Janssen Provides Update on IMBRUVICA® (ibrutinib) Phase 3 PHOENIX Trial in Newly Diagnosed Non-Germinal Center B Cell (Non-GCB) Subtype of Diffuse Large B-Cell Lymphoma (DLBCL)
Jun 01, 2018
IMBRUVICA® (ibrutinib) in Combination with Rituximab Showed Greater Efficacy Compared to Placebo Plus Rituximab in Patients with Waldenström's Macroglobulinemia, a Rare and Incurable Form of Non-Hodgkin's Lymphoma
Jun 01, 2018
Oncternal Announces Publication of Data from Phase 1 Trial of Cirmtuzumab in CLL in Cell Stem Cell
Feb 05, 2018
Information Update - Six unauthorized sexual enhancement products seized from Krish Convenience in Maple, ON, may pose serious health risks
Dec 15, 2017
UpScript Offers Teva's Generic of Viagra®